{"prompt": "['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 36 of 92', 'CR845-CLIN3102', 'regulatory agencies and Institutional Review Boards (IRBs)/Independent Ethics', 'Committees are notified, as appropriate.', 'Should the study be closed prematurely, all study materials (eg, completed, partially', 'completed, and blank eCRFs, as well as study drug) must be returned to the Sponsor or', 'destroyed at the site according to instructions which will be provided by the Sponsor, as', 'applicable.', '6.4', 'Treatments', 'Additional information on the study drug and its preparation, administration, storage,', 'supply, disposition, and accountability can be found in the Pharmacy Section of the', 'Investigator Site File (ISF).', '6.4.1', 'Treatments Administered', 'The study drug will be dispensed by qualified staff members who have received training', 'on study drug handling and administration.', 'Patients will receive IV CR845 at a dose of 0.5 mcg/kg or placebo after each dialysis', 'session, generally 3 times per week for up to 64 weeks (ie, 12 weeks double-blind and', '52 weeks open-label) as an IV bolus into the venous line of the dialysis circuit at the end', 'of each dialysis session and may be given either during or after rinse back of the dialysis', 'circuit. If a patient receives additional dialysis during a given week for any reason, an', 'additional dose of CR845 or placebo will be administered following dialysis. A maximum', 'of 4 doses per week is allowed. No additional doses will be given for patients receiving', 'an additional unscheduled ultrafiltration treatment.', 'Following the IV push of study drug, the venous line must be flushed with at least 10 mL', 'of normal saline.', \"The patient's prescription dry body weight (ie, the target post-dialysis weight, as\", \"determined by the patient's nephrologist or dialysis unit during screening) will be used to\", 'calculate the dose of the study drug to be administered throughout the Double-blind', 'Treatment Period.', 'During the Open-label Treatment Period, the volume of CR845 to be administered will be', \"based on patient's prescription target dry body weight recorded on Day 1 of the\", 'Open-label Treatment Period, and adjusted if prescription dry body weight changes by', '10% or more from dry body weight being used for calculation of CR845 dose.', '6.4.2', 'Identity of Investigational Product(s)', '6.4.2.1', 'Formulation of Study Drug', 'Study drug will be supplied by the Sponsor as a solution in 2-mL glass vials containing a', 'minimum extractable volume of 1.3 mL of CR845 at a concentration of 0.05 mg/mL in', '0.04 M isotonic acetate buffer, pH 4.5. The composition of the CR845 solution contains', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 38 of 95']['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 37 of 92', 'CR845-CLIN3102', 'CR845 (free base), acetic acid, sodium acetate trihydrate, sodium chloride, hydrochloric', 'acid, and water for injection.', 'Matching placebo (0.04M isotonic acetate buffer, pH 4.5) will be provided in 2-mL glass', 'vials containing a minimum extractable volume of 1.3 mL. The composition of the', 'placebo buffer solution is acetic acid, sodium acetate trihydrate, sodium chloride,', 'hydrochloric acid, and water for injection. The placebo buffer is identical to the buffer', 'solution used in the CR845 solution and has identical appearance as the solution', 'containing the active ingredient. The placebo buffer solution will be packaged, stored,', 'and shipped identically to the CR845 solution.', '6.4.2.2', 'Packaging, Labeling, and Storage Stability of Study Drug', 'Study drug will be shipped at 15\u00b0C to 30\u00b0C. Temperature will be monitored during', 'shipment and verified and recorded in the pharmacy log by pharmacist upon arrival at the', 'site. The vials must be stored at temperature ranging from 15\u00b0C to 30\u00b0C upon receipt and', 'temperature will be monitored accordingly.', 'For the Double-blind Treatment Period vials will be packaged (blinded) in boxed kits (also', 'blinded) containing 40 vials per box (4 extra vials for backup). Kits will be labeled with', 'patient ID number and kit number. A single box of vials will be assigned to a patient.', 'For the Open-label Treatment Period, vials will be packaged in boxed kits containing', '12 vials per box. Kits will be labeled with patient ID number and kit number. A single', 'box of vials will be assigned to a patient.', 'Labeling of the vials will include, but is not limited to, the following:', 'Study protocol number (CR845-CLIN3102)', 'Blinded name of study drug (CR845 0.5 mcg/kg or placebo IV solution) for the', 'Double-blind Treatment Period or name and concentration of study drug (CR845', '0.5 mcg/kg) for the Open-label Treatment Period', 'Batch or lot number (open-label only)', 'Temperature storage instructions (store at 15\u00b0C to 30\u00b0C)', 'Extractable volume: at least 1.3 mL', 'Name and location of Sponsor', 'Administer according to protocol', 'For Clinical Trial Use Only', 'The label on each kit will be the same as the label on an individual vial, and in addition,', 'will provide the number of vials contained per box (12 or 40). It will also include', '\"Caution: New Drug- Limited by Federal (or United States) Law to Investigational Use.\"', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 39 of 95']\n\n###\n\n", "completion": "END"}